Previous 10 | Next 10 |
Image source: The Motley Fool. Amarin (NASDAQ: AMRN) Q1 2021 Earnings Call Apr 29, 2021 , 7:30 a.m. ET Operator Continue reading For further details see: Amarin (AMRN) Q1 2021 Earnings Call Transcript
Amarin Corporation PLC (AMRN) Q1 2021 Earnings Conference Call April 29, 2021, 07:30 ET Company Participants Alina Doubrovna - Associate Manager, IR John Thero - President, CEO & Director Karim Mikhail - SVP & Commercial Head, Europe Michael Kalb - CFO, SVP & Assistant Secretary A...
The following slide deck was published by Amarin Corporation plc in conjunction with their 2021 Q1 earnings call. For further details see: Amarin Corporation plc 2021 Q1 - Results - Earnings Call Presentation
Amarin Corporation (AMRN) has gained ~1.2% in the pre-market despite a revenue miss in Q1 2021 financials.The quarterly total revenue has slipped ~8.3% YoY to $142.2M as net product revenue slumped ~7.1% YoY to $141.4M. Net product revenue from the U.S. has contracted by ~$4.7M or ~...
Amarin (AMRN): Q1 Non-GAAP EPS of $0.03 beats by $0.07; GAAP EPS of $0.00 beats by $0.05.Revenue of $142.17M (-8.3% Y/Y) misses by $4.93M.“Results in the first quarter of 2021 reflect a mixture of positive accomplishments and continued headwinds, particularly from COVID-19, the effects...
Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA® Growth in the United States Positioned to Increase as the Impact of COVID-19 Recedes Expenses Managed in Q1 2021 to Minimize Operating Loss Despite Rev...
DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced that Joseph T. Kennedy has informed the board of directors of his decision to retire as executive vice president, general counsel and strategic initiatives. A sear...
Amarin (NASDAQ:AMRN) is scheduled to announce Q1 earnings results on Thursday, April 29th, before market open.The consensus EPS Estimate is -$0.04 (-33.3% Y/Y) and the consensus Revenue Estimate is $147.1M (-5.1% Y/Y).Over the last 2 years, AMRN has beaten EPS estimates 88% of the time and ha...
The UK's Medicines and Healthcare Products Regulatory Agency ("MHRA") has granted marketing approval to Amarin (AMRN) for Vazkepa (icosapent ethyl) as a treatment to reduce the risk of cardiovascular events in statin-treated adult patients with elevated triglycerides.The move follows European...
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication 1,2, 3 VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization for European Union DUBLIN, Ireland and BRIDGEWATER, N.J...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...